Irinotecan
- Generic Name
- Irinotecan
- Brand Names
- Camptosar, Onivyde, Onivyde pegylated liposomal (previously known as Onivyde)
- Drug Type
- Small Molecule
- Chemical Formula
- C33H38N4O6
- CAS Number
- 97682-44-5
- Unique Ingredient Identifier
- 7673326042
- Background
Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. It is a derivative of camptothecin. Irinotecan was approved for the treatment of advanced pancreatic cancer in October, 2015 (irinotecan liposome injection, trade name Onivyde).
- Indication
For the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin). Also used in combination with cisplatin for the treatment of extensive small cell lung cancer. Irinotecan is currently under investigation for the treatment of metastatic or recurrent cervical cancer. Also used in combination with fluorouracil and leucovorin for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy.
- Associated Conditions
- Esophageal Cancer, Ewing's Sarcoma, Gastric Cancer, High Grade Glioma: Glioblastoma (GBM), Metastatic Cervical Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Cancer, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Stage IV Colorectal Cancer, Recurrent, metastatic Colorectal carcinoma, Refractory, metastatic Pancreatic adenocarcinoma
- Associated Therapies
- -
Irinotecan and Cediranib in Treating Patients With Metastatic Colorectal Cancer That Did Not Respond to Previous Oxaliplatin, Fluoropyrimidine, and Bevacizumab
- Conditions
- Colorectal Cancer
- Interventions
- Drug: cediranib maleateDrug: irinotecan hydrochloride
- First Posted Date
- 2008-01-09
- Last Posted Date
- 2017-04-05
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 5
- Registration Number
- NCT00588900
- Locations
- 🇺🇸
Cancer Resource Center - Lincoln, Lincoln, Nebraska, United States
🇺🇸Fort Wayne Medical Oncology and Hematology, Fort Wayne, Indiana, United States
🇺🇸CCOP - Northern Indiana CR Consortium, South Bend, Indiana, United States
A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Previously Untreated Metastatic Colorectal Cancer.
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2007-12-19
- Last Posted Date
- 2018-07-31
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT00577109
Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery
- Conditions
- Stage III Lung Cancer AJCC v7Stage IIIA Ovarian Cancer AJCC v6 and v7Hodgkin LymphomaMetastatic Malignant NeoplasmStage IIIC Colon Cancer AJCC v7Stage IIIC Ovarian Cancer AJCC v6 and v7Stage IV Breast Cancer AJCC v6 and v7Stage IV Colon Cancer AJCC v7Stage IV Lung Cancer AJCC v7Stage IV Ovarian Cancer AJCC v6 and v7
- Interventions
- Drug: Irinotecan HydrochlorideOther: Laboratory Biomarker AnalysisOther: Pharmacological StudyDrug: Veliparib
- First Posted Date
- 2007-12-19
- Last Posted Date
- 2023-02-06
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 36
- Registration Number
- NCT00576654
- Locations
- 🇺🇸
Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States
🇺🇸Yale University, New Haven, Connecticut, United States
Effect of Panitumumab on the Pharmacokinetics of Irinotecan
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2007-11-26
- Last Posted Date
- 2016-04-12
- Lead Sponsor
- Amgen
- Target Recruit Count
- 28
- Registration Number
- NCT00563316
- Locations
- 🇨🇦
Research Site, Toronto, Ontario, Canada
CT-322 in Treating Patients With Recurrent Glioblastoma Multiforme and Combination Therapy With Irinotecan
- Conditions
- Brain and Central Nervous System TumorsRecurrent Glioblastoma Multiforme
- Interventions
- Drug: CT-322Drug: irinotecan hydrochloride
- First Posted Date
- 2007-11-22
- Last Posted Date
- 2010-10-27
- Lead Sponsor
- Adnexus, A Bristol-Myers Squibb R&D Company
- Target Recruit Count
- 72
- Registration Number
- NCT00562419
- Locations
- 🇺🇸
University of Kentucky, Lexington, Kentucky, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
Study of Biomarkers in Patients Undergoing Chemotherapy for Metastatic Colorectal Cancer
- Conditions
- Colorectal Cancer
- First Posted Date
- 2007-11-16
- Last Posted Date
- 2011-05-16
- Lead Sponsor
- Centre Hospital Regional Universitaire de Limoges
- Target Recruit Count
- 200
- Registration Number
- NCT00559676
- Locations
- 🇫🇷
Centre Hospital Regional Universitaire de Limoges, Limoges, France
Cetuximab and Combination Chemotherapy in Treating Patients With Advanced or Metastatic Colorectal Cancer
- Conditions
- Colorectal Cancer
- First Posted Date
- 2007-11-16
- Last Posted Date
- 2011-05-13
- Lead Sponsor
- Institut Cancerologie de l'Ouest
- Target Recruit Count
- 80
- Registration Number
- NCT00559741
- Locations
- 🇫🇷
Centre Paul Papin, Angers, France
Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver and/or Lung
- Conditions
- Colorectal CancerMetastatic Cancer
- Interventions
- Biological: cetuximabBiological: filgrastimDrug: fluorouracilDrug: irinotecan hydrochlorideDrug: leucovorin calcium
- First Posted Date
- 2007-11-12
- Last Posted Date
- 2012-12-11
- Lead Sponsor
- National Cancer Institute, France
- Target Recruit Count
- 24
- Registration Number
- NCT00557102
- Locations
- 🇫🇷
CHU de Grenoble - Hopital Michallon, Grenoble, France
Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer
- Conditions
- Colorectal Cancer
- Interventions
- Biological: cetuximabDrug: fluorouracilDrug: irinotecan hydrochlorideDrug: leucovorin calciumDrug: oxaliplatin
- First Posted Date
- 2007-11-12
- Last Posted Date
- 2021-02-18
- Lead Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
- Target Recruit Count
- 42
- Registration Number
- NCT00556413
- Locations
- 🇫🇷
Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle, Montpellier, France
Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer
- Conditions
- Stage III Colon CancerAdenocarcinoma of the ColonStage III Rectal CancerStage IV Rectal CancerAdenocarcinoma of the RectumRecurrent Colon CancerRecurrent Rectal CancerStage IV Colon Cancer
- Interventions
- Biological: pertuzumabBiological: cetuximabDrug: irinotecan hydrochlorideOther: immunohistochemistry staining methodOther: fluorescence in situ hybridizationOther: gene expression analysisOther: mutation analysisOther: polymerase chain reactionOther: laboratory biomarker analysis
- First Posted Date
- 2007-10-31
- Last Posted Date
- 2015-03-31
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 17
- Registration Number
- NCT00551421
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.